Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001193125-25-116082
Filing Date
2025-05-08
Accepted
2025-05-08 17:25:12
Documents
10

Document Format Files

Seq Description Document Type Size
1 S-3 d932224ds3.htm S-3 440938
2 EX-4.9 d932224dex49.htm EX-4.9 294645
3 EX-4.11 d932224dex411.htm EX-4.11 95690
4 EX-4.12 d932224dex412.htm EX-4.12 95768
5 EX-4.13 d932224dex413.htm EX-4.13 84623
6 EX-5.1 d932224dex51.htm EX-5.1 28571
7 EX-23.1 d932224dex231.htm EX-23.1 1688
8 EX-FILING FEES d932224dexfilingfees.htm EX-FILING FEES 27449
9 GRAPHIC g932224dsp1.jpg GRAPHIC 4353
10 GRAPHIC g932224g11a01.jpg GRAPHIC 36739
  Complete submission text file 0001193125-25-116082.txt   1127404
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-287104 | Film No.: 25927508
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)